Erisipelas and its Management in a Tertiary Care Hospital
Main Article Content
Abstract
Erysipelas is an acute dermo-hypodermic (non-necrotizing) infection of bacterial origin, mainly group A beta-hemolytic streptococcus. The lower limbs are affected in more than 80% of cases and the risk factors identified are skin barrier breakdown, lymphedema and obesity. Diagnosis is clinical and is based on the association of an acute inflammatory plaque with fever, lymphangitis, lymphadenopathy and leukocytosis. Bacteriology is generally not useful due to low sensitivity or late positivity. In atypical forms, erysipelas should be distinguished from necrotizing fasciitis and acute venous thrombosis. Penicillin remains the gold standard treatment, although new drugs may be used, given their pharmacodynamic profile. Recurrence is the main complication, being crucial the correct treatment of risk factors1.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Caetano M, Amorin I. Erisipela [Erysipelas]. Acta Med Port. 2005 SepOct;18(5):385-93. Portuguese. Epub 2005 Oct 16. PMID: 16611543
II. Wessels MR. Choosing an Antibiotic for Skin Infections. N Engl J Med. 2015;372(12):1164–5.
III. Ellis Simonsen SM, Van Orman ER, Hatch BE, Jones SS, Gren LH, Hegmann KT, et al. Cellulitis incidence in a defined population. Epidemiol Infect 2006;134:293–9.
IV. Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med. 1992;93:543–8.
V. Ferreira A, Bolland MJ, Thomas MG. Metaanalysis of randomised trials comparing a penicillin or cephalosporin with a macrolide or lincosamide in the treatment of cellulitis or erysipelas. Infection 2016;44:607-15.
VI. Wessels MR. Choosing an Antibiotic for Skin Infections. N Engl J Med. 2015;372(12):1164–5.
VII. Olmos E, Bonilla CE. Infección por Streptococcus y Staphylococcus en dermatología. En Olmos E: Texto de dermatología 25 años Hospital de San José. Bogotá: Sociedad de Cirugía de Bogotá; 2007, p. 187-203.
VIII. Camilleri MJ, Daniel Su WP. Panniculitis. En: Freedberg IM, Eisen AZ, Wolf K, Austen KF, Goldsmith LA, Katz S: Fitzpatrick's dermatology in general medicine, 6th ed; 2003. p.1275-8.
IX. Swartz MN, Pastemack MS. Skin and soft tissue infections. En Mandell GL, Bennett JE, Dolin R: Principles and practice of infectious disease. 6th ed. Philadelphia: Churchill Livingstone; 2005, p.1172-84.
X. Stevens DL. Cellulitis, pyoderma, abscesses and other skin and subcutaneous infections. En: Cohen J, Powderly WG: Infectous diseases. 2nd ed. Philadelphia: Mosby Elsevier; 2004. p. 133-55.
XI. Vaillant L. Critères diagnostiques de l'érysipèle [Diagnostic criteria for erysipelas]. Ann Dermatol Venereol. 2001 Mar;128(3 Pt 2):326-33. French. PMID: 11319359.
XII. Wang YF, Que HF, Wang YJ, Cui XJ. Chinese herbal medicines for skin and soft tissue infections. Cochrane Database Syst Rev. 2013;2013(6).
XIII. Quéré I, Nagot N, Vikkula M. Incidence of Cellulitis among Children with Primary Lymphedema. N Engl J Med. 2018;378(21):2047–8.
XIV. Swartz MN. Cellulitis. 2004;904–12.
XV. Norimatsu Y, Ohno Y. Predictors for readmission due to cellulitis among Japanese patients. J Dermatol. 2021;48(5):681–4.
XVI. Raff AB, Kroshinsky D. Cellulitis a review. JAMA - J Am Med Assoc. 2016;316(3):325– 37
XVII. Bd B, Kl HW. Cellulitis Pathophysiology Treatment / Management Di erential Diagnosis. 2020;1–5